A federal judge is set to sentence Purdue Pharma on criminal charges tied to its role in fueling the opioid crisis, a procedural step that would unlock billions of dollars in settlement funds for victims, states, and treatment programs across the country.
The sentencing, which was delayed by one week so opioid victims could attend in person, centers on a $225 million forfeiture order the judge is expected to impose. That forfeiture is not just a penalty. It is a gateway. Once the court enters it, the broader settlement covering nearly all opioid lawsuits against Purdue can finally take effect.
The stakes are enormous. The deal would dissolve Purdue Pharma entirely and require members of the Sackler family to pay up to $7 billion over 15 years. In its place, a new public-benefit company called Knoa Pharma would rise from the wreckage, its mission reoriented toward addressing the crisis Purdue helped create.
Purdue Pharma pleaded guilty to federal criminal charges related to its marketing and distribution of OxyContin, the prescription painkiller that became a flashpoint in America's opioid epidemic. The sentencing hearing will formalize the consequences of that plea.
The judge's expected $225 million forfeiture order to the Justice Department represents the criminal side of Purdue's accountability. But the real weight of the resolution sits on the civil side, where the broader settlement would resolve virtually every remaining lawsuit tied to the company's conduct.
As ABC News reported, the sentencing clears one of the last procedural hurdles before settlement money can begin flowing to communities devastated by opioid addiction and overdose deaths.
The settlement has drawn sharp criticism from some quarters, and the reason is straightforward: it would provide members of the Sackler family with a legal shield against future civil lawsuits. The family, which privately owned Purdue Pharma and extracted billions in profits from OxyContin sales, would pay up to $7 billion under the deal. In exchange, they would walk away from further personal liability.
That tradeoff sat before the U.S. Supreme Court for months. As Newsmax noted, the proposed nationwide settlement "would allocate billions of dollars to combat the opioid epidemic, but also provide a legal shield for members of the Sackler family who own the company." The deal had been on hold while the justices reviewed whether a bankruptcy court could grant that kind of broad liability protection to individuals who had not themselves filed for bankruptcy.
The legal question was not trivial. Critics argued that shielding the Sacklers from lawsuits stripped victims of their day in court. Supporters countered that without the shield, the Sacklers would never agree to pay $7 billion, and the money would vanish into decades of litigation.
The opioid crisis tied to Purdue Pharma did not happen by accident. The company aggressively marketed OxyContin from the moment it launched the drug in the mid-1990s. At a 1996 event rallying Purdue's sales force, Richard Sackler described the goal in terms that would later haunt the family. He spoke of a "blizzard of prescriptions" the company intended to generate.
That blizzard arrived. OxyContin became one of the most widely prescribed painkillers in the country. Communities that had never dealt with widespread addiction found themselves overwhelmed. Rural counties, small cities, and working-class neighborhoods bore the heaviest toll. Overdose deaths climbed year after year, and the crisis eventually expanded beyond prescription pills into heroin and fentanyl.
The human cost is staggering and still growing. The settlement funds are intended to address treatment, prevention, and recovery programs, but no dollar figure can undo the damage already done.
The criminal sentencing itself carries a specific and limited function. The $225 million forfeiture satisfies the federal government's criminal case against Purdue as a corporate entity. No individual Sackler family member faces criminal charges in this proceeding.
Once the forfeiture is entered, the broader civil settlement can move toward final implementation. That means states, cities, counties, tribal nations, and individual claimants who signed on to the deal can begin receiving funds. Purdue Pharma would cease to exist as a corporate entity. Knoa Pharma, the new public-benefit company, would take over operations with a mandate that looks nothing like Purdue's original profit-driven model.
The judge's decision to delay the hearing by one week to let victims attend in person signals an awareness that this proceeding carries weight beyond its procedural function. For families who lost loved ones to opioid addiction, the courtroom moment matters.
The Purdue Pharma case has always tested the boundaries of corporate accountability. A company can plead guilty. A company can be dissolved. A company can forfeit hundreds of millions of dollars. But a company cannot go to prison.
The Sackler family's $7 billion payment is the largest personal financial consequence any family has faced in the opioid litigation. Whether it constitutes justice depends on who you ask. Victims' advocates have called it insufficient. Pragmatists have called it the best deal available given the legal realities. The family has maintained that Purdue's conduct was lawful, a position that sits uncomfortably next to the company's guilty plea.
Investigators and prosecutors spent years building the case against Purdue. The company admitted to conduct that fueled the worst drug crisis in American history. The sentencing hearing puts a formal punctuation mark on that admission.
Once the sentencing is complete and the forfeiture order is entered, attention will shift to the mechanics of distributing settlement funds. States and local governments have already been negotiating how to allocate the money. Treatment centers, first responders, and public health agencies across the country stand to receive direct funding.
The transition from Purdue Pharma to Knoa Pharma will also require oversight. The new entity's public-benefit structure is designed to prevent a repeat of the profit-driven decisions that turned a painkiller into a national catastrophe. Whether that structure holds will depend on the governance framework and the willingness of regulators to enforce it.
Authorities have not publicly confirmed the full timeline for fund distribution or the specific oversight mechanisms that will govern Knoa Pharma's operations. Those details will matter as much as the headline dollar figures.
The opioid crisis killed hundreds of thousands of Americans and hollowed out communities that still have not recovered. A courtroom proceeding cannot fix that. But it can establish, on the public record, that the company responsible has been held to account under the law, and that the money owed is finally on its way.
